British pharmaceutical and services company Clinigen Group PLC has inked an agreement with Swiss peer Novartis to buy the U.S. rights to Proleukin.
Clinigen Group will purchase the U.S. rights of the metastatic renal cell carcinoma treatment for up to $210 million in cash.
With the transaction, Clinigen will be the exclusive international owner of the licensed version of Proleukin, which is being used in multiple drug studies across different disease areas.
In July 2018, Clinigen bought the rights to Proleukin outside the U.S. The company said that Proleukin generated $60 million in revenue in the U.S. for the year leading up to June 30, 2018.